Akuru Pharma has been granted a total of 600,000 SEK from Sten K Johnsons Foundation and from Vinnova’s Runner up SME Instruments. Most of the sum comes from Vinnova, which handles the European Commission’s call for proposals for Horizon2020 SME instrument.
This funding will be used partly to advance the company’s plan for diagnostic and therapeautic development for kidney cancer, and to promote further commercial development. The company is currently sponsoring an ongoing clinical phase 2 study in diagnosis of clear cell kidney cancer. In conjunction with Vinnova funding, the company received an “seal of excellence” certificate. Akuru Pharma is also planning to apply for further funding from Horizon2020 SME Instrument to fund the subsequent steps in development. “We are proud and happy to be granted this funding, which enables us to proceed with our “proof of concept” clinical study and to continue developing the concept. This is indeed a confirmation that we are on the right track, says Håkan Axelson, founder and chairman of Akuru Pharma.